Education
About Us
Working with TipRanks
Follow Us
Viatris (VTRS)
NASDAQ:VTRS
VTRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.85 - $13.55
Previous CloseN/A
Volume2.11M
Average Volume (3M)15.20M
Market Cap
$10.05B
Enterprise Value$28.34B
Total Cash (Recent Filing)$291.30M
Total Debt (Recent Filing)$8.04B
Price to Earnings (P/E)―
Beta0.76
Next Earnings
May 08, 2025EPS Estimate
0.5Last Dividend Ex-Date
Mar 10, 2025Dividend Yield5.75%
Share Statistics
EPS (TTM)-0.53
Shares Outstanding1,193,688,700
10 Day Avg. Volume10,908,197
30 Day Avg. Volume15,195,425
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.04
Enterprise Value/Ebitda9.71
Forecast
1Y Price Target
$10.75Price Target Upside27.67% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityViatris plans to be more aggressive with buybacks, supported by its financial flexibility and a substantial amount of free cash flow.
Market PerformanceManagement is confident about the company's performance in China, which has exceeded initial expectations.
Revenue GrowthThe company's pipeline and diversification, with a significant number of new product submissions annually, provide visibility into sustainable revenue growth.
Bears Say
Earnings GuidanceViatris’ 4Q update was highlighted by disappointing FY25 EBITDA guidance (-8% below consensus).
Growth ProspectsViatris has limited potential for upward revisions and lacks clinical catalysts for 2025, which affects its growth prospects.
Regulatory ImpactThe biggest surprise in the 4Q update was the generic Revlimid impact, which is on the import ban list ($200m lost revenue at an >95% gross margin).
---
Ownership Overview
0.23% Insiders
23.51% Mutual Funds
0.25% Other Institutional Investors
46.67% Public Companies and
Individual Investors
VTRS FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest stock price was $6.85 and its highest was $13.55 in the past 12 months.
What is Viatris’s market cap?
Viatris’s market cap is $10.05B.
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is May 08, 2025 which is in 6 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Feb 27, 2025. The company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.572 by -$0.032.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Undervalued.
Does Viatris pay dividends?
Viatris pays a Quarterly dividend of $0.119 which represents an annual dividend yield of 5.75%. See more information on Viatris dividends here
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is 0.5.
How many shares outstanding does Viatris have?
Viatris has 1,193,688,700 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of $0.54 in its last earnings report, missing expectations of $0.572. Following the earnings report the stock price went down -15.225%.
Which hedge fund is a major shareholder of Viatris?
Currently, no hedge funds are holding shares in VTRS
---
Viatris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.75 (27.67% Upside)
$10.75 (27.67% Upside)
Blogger Sentiment
Bullish
VTRS Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $346.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.02%
12-Months-Change
Fundamentals
Return on Equity
-3.24%
Trailing 12-Months
Asset Growth
-12.97%
Trailing 12-Months
Company Description
Viatris
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
---
VTRS Company Deck
---
VTRS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While Viatris reported growth in revenues and made significant strides in debt reduction and pipeline development, the Indore facility challenges pose a substantial negative impact on 2025 financials. The company is actively addressing these issues, but the overall sentiment is balanced with significant achievements and challenges.Read More>---
VTRS Net sales Breakdown
60.77% Developed Markets
15.32% Emerging Markets
14.75% Greater China
9.16% JANZ
---
VTRS Stock 12 Month Forecast
Average Price Target
$10.75
▲(27.67% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
―
Amneal Pharmaceuticals
―
---